What is Trially?
Trially operates as an AI-native platform focused on revolutionizing patient recruitment for clinical trials. By leveraging advanced artificial intelligence, the company enhances accuracy in matching and enrolling patients, which directly contributes to boosting enrollment rates and minimizing costly screen failures and prescreening inefficiencies. Trially's technology is trusted by clinical sites, pharmaceutical sponsors, and physicians, offering a secure and compliant solution to expedite the complex landscape of clinical research.
How much funding has Trially raised?
Trially has raised a total of $4.7M across 1 funding round:
Seed
$4.7M
Seed (2025): $4.7M with participation from Flyover Capital, Alpaca, Looking Glass Capital, Redbud Brands, Atria, The Council, Gaingels, and Blu Ventures
Key Investors in Trially
Flyover Capital
Flyover Capital is an investment firm focused on supporting early-stage technology leaders, providing resources and strategic support to drive generational growth.
Alpaca
Alpaca VC specializes in real estate and commerce startups, offering expertise in deal structuring and growth support to founders at the intersection of physical and digital worlds.
Looking Glass Capital
Looking Glass Capital invests in mission-driven founders at early stages, focusing on non-consensus opportunities in health, climate, and empowerment sectors.
What's next for Trially?
The substantial enterprise-level funding and recent strategic investment position Trially for accelerated growth and market expansion. This capital infusion is expected to fuel further development of its AI capabilities, enhance its platform's reach across more clinical trial networks, and potentially explore new therapeutic areas. Trially's focus on improving efficiency and accuracy in clinical trial recruitment aligns with the growing demand for faster drug development cycles, suggesting a trajectory towards becoming a dominant player in the clinical research technology sector.
See full Trially company page
